Targeting Signal Transduction Pathways in Hematopoietic Disorders
Author:
Zhou Li,Verma Amit
Publisher
Springer New York
Reference102 articles.
1. Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E., Thomas, D., Koller, C., Estrov, Z., O'Brien, S., Keating, M., et al. 2000. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96 :2240–2245. 2. Aizawa, S., Nakano, M., Iwase, O., Yaguchi, M., Hiramoto, M., Hoshi, H., Nabeshima, R., Shima, D., Handa, H., and Toyama, K. 1999. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro . Leuk Res 23:239–246. 3. Aizawa, S., Hiramoto, M., Hoshi, H., Toyama, K., Shima, D., and Handa, H. 2000. Establishment of stromal cell line from an MDS RA patient which induced an apoptotic change in hematopoietic and leukemic cells in vitro . Exp Hematol 28:148–155. 4. Akiyama, T., Matsunaga, T., Terui, T., Miyanishi, K., Tanaka, I., Sato, T., Kuroda, H., Takimoto, R., Takayama, T., Kato, J., et al. 2005. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis . Leukemia 19:1558–1566. 5. Allampallam, K., Shetty, V., Hussaini, S., Mazzoran, L., Zorat, F., Huang, R., and Raza, A. 1999. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes . Anticancer Res 19:5323–5328.
|
|